http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 15 Sep 2026 09:35:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+to+Expand+Bucillamine+IP+and+Orphan+Drug+Portfolio+Across+Medical+Countermeasures+and+Rare+Diseases/27062653.html <p><i><strong>Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs</strong></i></p> <p><strong id="dateline">TORONTO, ON / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 15, 2026 / </strong>Revive Therapeutics Ltd. ("Revive" or the "Company") (OTC<span style="background-color:rgb(255,255,255);color:rgb(73,80,87);">QB</span>:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today outlined its strategy to strengthen and expand the intellectual property and regulatory portfolio supporting bucillamine across medical countermeasures ("MCMs") and rare diseases.</p><p>Revive's objective is to build bucillamine into a differentiated therapeutic franchise with multiple potential development and http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+to+Expand+Bucillamine+IP+and+Orphan+Drug+Portfolio+Across+Medical+Countermeasures+and+Rare+Diseases/27062653.html Tue, 15 Sep 2026 09:35:00 -0400 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+to+Expand+Bucillamine+IP+and+Orphan+Drug+Portfolio+Across+Medical+Countermeasures+and+Rare+Diseases/27062653.html <p><i><strong>Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs</strong></i></p> <p><strong id="dateline">TORONTO, ON / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 15, 2026 / </strong>Revive Therapeutics Ltd. ("Revive" or the "Company") (OTC<span style="background-color:rgb(255,255,255);color:rgb(73,80,87);">QB</span>:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today outlined its strategy to strengthen and expand the intellectual property and regulatory portfolio supporting bucillamine across medical countermeasures ("MCMs") and rare diseases.</p><p>Revive's objective is to build bucillamine into a differentiated therapeutic franchise with multiple potential development and http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+to+Expand+Bucillamine+IP+and+Orphan+Drug+Portfolio+Across+Medical+Countermeasures+and+Rare+Diseases/27062653.html Tue, 15 Sep 2026 09:35:00 -0400 RVV RVVTF http://www.streetinsider.com/ACCESS+Newswire/Revive+Therapeutics+to+Expand+Bucillamine+IP+and+Orphan+Drug+Portfolio+Across+Medical+Countermeasures+and+Rare+Diseases/27062653.html <p><i><strong>Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs</strong></i></p> <p><strong id="dateline">TORONTO, ON / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 15, 2026 / </strong>Revive Therapeutics Ltd. ("Revive" or the "Company") (OTC<span style="background-color:rgb(255,255,255);color:rgb(73,80,87);">QB</span>:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today outlined its strategy to strengthen and expand the intellectual property and regulatory portfolio supporting bucillamine across medical countermeasures ("MCMs") and rare diseases.</p><p>Revive's objective is to build bucillamine into a differentiated therapeutic franchise with multiple potential development and http://www.streetinsider.com/ACCESS+Newswire/Revive+Therapeutics+to+Expand+Bucillamine+IP+and+Orphan+Drug+Portfolio+Across+Medical+Countermeasures+and+Rare+Diseases/27062653.html Tue, 15 Sep 2026 09:35:00 -0400 RVV RVVTF http://www.streetinsider.com/ACCESS+Newswire/Revive+Therapeutics+to+Expand+Bucillamine+IP+and+Orphan+Drug+Portfolio+Across+Medical+Countermeasures+and+Rare+Diseases/27062653.html <p><i><strong>Company aims to build a globally protected bucillamine franchise spanning medical countermeasures, orphan diseases and government preparedness programs</strong></i></p> <p><strong id="dateline">TORONTO, ON / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 15, 2026 / </strong>Revive Therapeutics Ltd. ("Revive" or the "Company") (OTC<span style="background-color:rgb(255,255,255);color:rgb(73,80,87);">QB</span>:RVVTF)(CSE:RVV)(Frankfurt:31R), a life sciences company focused on the research and development of therapeutics for biodefence and pandemic preparedness, today outlined its strategy to strengthen and expand the intellectual property and regulatory portfolio supporting bucillamine across medical countermeasures ("MCMs") and rare diseases.</p><p>Revive's objective is to build bucillamine into a differentiated therapeutic franchise with multiple potential development and http://www.streetinsider.com/ACCESS+Newswire/Revive+Therapeutics+to+Expand+Bucillamine+IP+and+Orphan+Drug+Portfolio+Across+Medical+Countermeasures+and+Rare+Diseases/27062653.html Tue, 15 Sep 2026 09:35:00 -0400 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html <p align="left">TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its ongoing research study evaluating Bucillamine as a potential treatment for nerve agent exposure. The study is being conducted in collaboration with Defence R&amp;D Canada – Suffield Research Centre (“DRDC”), an agency within the Canadian Department of National Defence that provides extensive expertise, infrastructure, and scientific capabilities to support the development of medical http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Provides+Update+of+Key+Nerve+Agent+Countermeasure+Study/25648483.html Fri, 21 Nov 2025 12:07:00 -0400 31R A.50213784 O.08407916 O.15873108 RVV RVVTF http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html <p>Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.</p> <p>Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.</p> <p>The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.</p> <p>The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html Fri, 19 Sep 2025 17:00:39 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html <p>Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.</p> <p>Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.</p> <p>The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.</p> <p>The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html Fri, 19 Sep 2025 17:00:39 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html <p>Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.</p> <p>Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.</p> <p>The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.</p> <p>The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html Fri, 19 Sep 2025 17:00:39 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html <p>Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) announced the completion of a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit for gross proceeds of $91,400.</p> <p>Each unit consists of one common share and one warrant. The warrants allow holders to purchase additional common shares at $0.05 each within 36 months of the closing date.</p> <p>The company stated it will use proceeds for working capital and to pay certain trade payables. All securities issued are subject to a hold period expiring January 19, 2026.</p> <p>The Toronto-based life sciences company previously announced the private placement on September 5, 2025, according http://www.streetinsider.com/Equity+Offerings/Revive+Therapeutics+closes+second+tranche+of+private+placement+for+%2491%2C400/25356220.html Fri, 19 Sep 2025 17:00:39 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html <p align="left">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.</p> <p>Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html Fri, 19 Sep 2025 17:00:00 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html <p align="left">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.</p> <p>Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html Fri, 19 Sep 2025 17:00:00 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html <p align="left">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.</p> <p>Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html Fri, 19 Sep 2025 17:00:00 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html <p align="left">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.</p> <p>Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire http://www.streetinsider.com/Press+Releases/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html Fri, 19 Sep 2025 17:00:00 -0400 31R O.15873108 RVV RVVTF http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html <p align="left">TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed a second tranche of its previously announced private placement (see press release of September 5, 2025) by issuing 4,352,381 units, at a price of $0.021 per unit, for gross proceeds to Revive of $91,400.</p> <p>Each unit is comprised of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire http://www.streetinsider.com/Globe+Newswire/Revive+Therapeutics+Announces+Closing+of+Second+Tranche+of+Private+Placement/25356218.html Fri, 19 Sep 2025 17:00:00 -0400 31R O.15873108 RVV RVVTF